News
OTTAWA – The CADTH Board of Directors announced today that Suzanne McGurn has been appointed as the next President and Chief Executive Officer of CADTH, effective July 6, 2020.
Ms. McGurn will succeed Dr. Brian O’Rourke, who announced his retirement from CADTH in October 2019 after serving as President and Chief Executive Officer since 2010. D...
CADTH has received the following notice(s) of pending drug submission(s).
Brand name
TBC
Generic name
etonogestrel
Manufacturer
Merck Canada Inc.
Indication(s)
Prevention of pregnancy
Project Number
SR0648-000
Call for patient input
2020-05-06
Patient input deadlin...
In light of the COVID-19 pandemic, we’ve made some changes to our CADTH Scientific Advice Program activities. During this challenging and uncertain time, we recognize that clinical experts may not be available to participate in our projects. As input from Canadian clinical experts is key to producing high-quality and relevant advice, we’ve decid...
CADTH has received the following notice(s) of pending drug submission(s).
Brand name
Entyvio
Generic name
vedolizumab
Manufacturer
Takeda Canada Inc.
Indication(s)
Crohn’s disease
Project Number
SR0647-000
Call for patient input
2020-05-05
Patient input deadline
...
CADTH is here to answer your questions about COVID-19.
We’ve collected relevant information from CADTH and other respected organizations and published it on our new CADTH/COVID-19 web portal.
On this site, you’ll find evidence, tools, and resources covering a range of COVID-19 topics including prevention, testing, and treatment. Although some ...
